Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

6UJ9

Crystal structure of HLA-B*07:02 with R140Q mutant IDH2 peptide in complex with Fab

Summary for 6UJ9
Entry DOI10.2210/pdb6uj9/pdb
DescriptorHLA class I histocompatibility antigen, B-7 alpha chain, Beta-2-microglobulin, Isocitrate dehydrogenase [NADP], mitochondrial, ... (9 entities in total)
Functional Keywordshla-b7, mhc-i, immunotherapy, idh2, immune system
Biological sourceHomo sapiens (Human)
More
Total number of polymer chains5
Total formula weight97767.39
Authors
Miller, M.S.,Thirawatananond, P.,Aytenfisu, T.Y.,Wright, K.,Gabelli, S.B. (deposition date: 2019-10-02, release date: 2021-05-05, Last modification date: 2024-11-06)
Primary citationHwang, M.S.,Miller, M.S.,Thirawatananond, P.,Douglass, J.,Wright, K.M.,Hsiue, E.H.,Mog, B.J.,Aytenfisu, T.Y.,Murphy, M.B.,Aitana Azurmendi, P.,Skora, A.D.,Pearlman, A.H.,Paul, S.,DiNapoli, S.R.,Konig, M.F.,Bettegowda, C.,Pardoll, D.M.,Papadopoulos, N.,Kinzler, K.W.,Vogelstein, B.,Zhou, S.,Gabelli, S.B.
Structural engineering of chimeric antigen receptors targeting HLA-restricted neoantigens.
Nat Commun, 12:5271-5271, 2021
Cited by
PubMed Abstract: Chimeric antigen receptor (CAR) T cells have emerged as a promising class of therapeutic agents, generating remarkable responses in the clinic for a subset of human cancers. One major challenge precluding the wider implementation of CAR therapy is the paucity of tumor-specific antigens. Here, we describe the development of a CAR targeting the tumor-specific isocitrate dehydrogenase 2 (IDH2) with R140Q mutation presented on the cell surface in complex with a common human leukocyte antigen allele, HLA-B*07:02. Engineering of the hinge domain of the CAR, as well as crystal structure-guided optimization of the IDH2-HLA-B*07:02-targeting moiety, enhances the sensitivity and specificity of CARs to enable targeting of this HLA-restricted neoantigen. This approach thus holds promise for the development and optimization of immunotherapies specific to other cancer driver mutations that are difficult to target by conventional means.
PubMed: 34489470
DOI: 10.1038/s41467-021-25605-4
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.9 Å)
Structure validation

237423

PDB entries from 2025-06-11

PDB statisticsPDBj update infoContact PDBjnumon